miR-34a靶向调控HDAC1基因对急性髓系白血病细胞凋亡的影响
|
摘要
目的:探讨急性髓系白血病细胞中miR-34a对HDAC1的调控作用以及对细胞凋亡的影响。方法:将miR-34a mimics、miR-34a inhibitor、miR-34a scramble转染到HL-60细胞中,采用CCK8试验和流式细胞术分别检测miR-34a不同表达水平对HL-60细胞增殖和凋亡的影响。应用Western blot检测miR-34a表达改变后HDAC1蛋白表达水平。构建含HDAC1 3′UTR的双荧光素酶报告载体,应用双荧光素酶报告实验验证miR-34a与HDAC1的作用位点。构建不含HDAC1 3′UTR的表达载体,应用回复实验验证miR-34a与HDAC1的相互作用。结果:miR-34a过表达可导致HL-60细胞的增殖抑制、凋亡率增加。生物信息学分析表明,HDAC1是miR-34a的靶基因;Western blot结果显示,miR-34a高表达可下调HDAC1蛋白表达,双荧光素酶实验和回复实验显示,miR-34a可作用于HDAC1 3′UTR区,调理其表达。结论:miR-34a促进HL-60细胞凋亡,其作用可能与其对HDAC1表达调控有关。
Objective: To investigate the regulation of miR-34 a on HDAC1 expression and its effect on the apoptosis of acute myeloid leukemia(AML) cells. Methods: miR-34 a mimics, miR-34 a inhibitor and miR-34 a scramble were transfected into HL-60 cells. The effects of miR-34 a expression levels on proliferation and apoptosis of HL-60 cell were detected by CCK8 assay and flow cytometry respectively. The expression of HDAC1 protein was assessed by Western blot after regulating miR-34 a expression, the 3'UTR of HDAC1 was cloned and ligated to construct a dual luciferase reporter vector,and then the dual luciferase reporter assay was applied to verify the target of miR-34 a, the expression vector pcDNA3.1-HDAC1 was constructed, the interaction of miR-34 a and HDAC1 was analyzed by reversion test. Results: miR-34 a overexpression could inhibit the proliferation of HL-60 cells and induce their apoptosis. Bioinformatics analysis indicated that the HDAC1 was a target gene of miR-34 a. Western blot indicated that miR-34 a overexpression down-regulated the expression of HDAC1. Dual luciferase reporter assay and reversion test showed that miR-34 a could act at the 3-UTR of HDAC1 gene to regulate its expression. Conclusion: miR-34 a promotes the apoptosis of HL-60 cells via regulating HDAC1 expression.
Objective: To investigate the regulation of miR-34 a on HDAC1 expression and its effect on the apoptosis of acute myeloid leukemia(AML) cells. Methods: miR-34 a mimics, miR-34 a inhibitor and miR-34 a scramble were transfected into HL-60 cells. The effects of miR-34 a expression levels on proliferation and apoptosis of HL-60 cell were detected by CCK8 assay and flow cytometry respectively. The expression of HDAC1 protein was assessed by Western blot after regulating miR-34 a expression, the 3'UTR of HDAC1 was cloned and ligated to construct a dual luciferase reporter vector,and then the dual luciferase reporter assay was applied to verify the target of miR-34 a, the expression vector pcDNA3.1-HDAC1 was constructed, the interaction of miR-34 a and HDAC1 was analyzed by reversion test. Results: miR-34 a overexpression could inhibit the proliferation of HL-60 cells and induce their apoptosis. Bioinformatics analysis indicated that the HDAC1 was a target gene of miR-34 a. Western blot indicated that miR-34 a overexpression down-regulated the expression of HDAC1. Dual luciferase reporter assay and reversion test showed that miR-34 a could act at the 3-UTR of HDAC1 gene to regulate its expression. Conclusion: miR-34 a promotes the apoptosis of HL-60 cells via regulating HDAC1 expression.
引文
1 Zhao J,Xie C,Edwards H,et al.Histone deacetylases 1 and 2cooperate in regulating BRCA1,CHK1,and RAD51 expression in acute myeloid leukemia cells.Oncotarget,2017;8(4):6319-6329.
2 Wang X,Chen H,Bai J,et al.MicroRNA:an important regulator in acute myeloid leukemia.Cell Biol Int,2017;41(9):936-945.
3 Ghandadi M,Sahebkar A.MicroRNA-34a and its target genes:Key factors in cancer multidrug resistance.Curr Pharm Des,2016;22(7):933-939.
4 Hermeking H.The miR-34 family in cancer and apoptosis.Cell Death Differ,2010;17(2):193-199.
5 Cui X,Zhao Z,Liu D,et al.Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma.JExp Clin Cancer Res,2014;33(20):1-11.
6 Wang X,Li J,Dong K,et al.Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.Cell Signal,2015;27(3):443-452.
7 Pulikkan JA,Peramangalam PS,Dengler V,et al.C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.Blood,2010;116(25):5638-5649.
8 Ropero S,Esteller M.The role of histone deacetylases(HDACs)in human cancer.Mol Oncol,2007;1(1):19-25.
9 Li X,Xu W.HDAC1/3 dual selective inhibitors-new therapeutic agents for the potential treatment of cancer.Drug Discov Ther,2014;8(5):225-228.
10 Matthews GM,Mehdipour P,Cluse LA,et al.Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.Blood,2015;126(21):2392-2403.
11 Stubbs MC,Kim W,Bariteau M,et al.Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL.Clin Cancer Res,2015;21(10):2348-2358.
2 Wang X,Chen H,Bai J,et al.MicroRNA:an important regulator in acute myeloid leukemia.Cell Biol Int,2017;41(9):936-945.
3 Ghandadi M,Sahebkar A.MicroRNA-34a and its target genes:Key factors in cancer multidrug resistance.Curr Pharm Des,2016;22(7):933-939.
4 Hermeking H.The miR-34 family in cancer and apoptosis.Cell Death Differ,2010;17(2):193-199.
5 Cui X,Zhao Z,Liu D,et al.Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma.JExp Clin Cancer Res,2014;33(20):1-11.
6 Wang X,Li J,Dong K,et al.Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.Cell Signal,2015;27(3):443-452.
7 Pulikkan JA,Peramangalam PS,Dengler V,et al.C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.Blood,2010;116(25):5638-5649.
8 Ropero S,Esteller M.The role of histone deacetylases(HDACs)in human cancer.Mol Oncol,2007;1(1):19-25.
9 Li X,Xu W.HDAC1/3 dual selective inhibitors-new therapeutic agents for the potential treatment of cancer.Drug Discov Ther,2014;8(5):225-228.
10 Matthews GM,Mehdipour P,Cluse LA,et al.Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.Blood,2015;126(21):2392-2403.
11 Stubbs MC,Kim W,Bariteau M,et al.Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL.Clin Cancer Res,2015;21(10):2348-2358.